Abstract:Introduction/Background: Deep neural networks have shown great promise in advancing drug discovery and precision medicine. By leveraging large amounts of complex biomedical and chemical data, deep learning approaches can identify novel targets, predict drug-target and drug-drug interactions, generate new molecular structures, and assist in personalized treatment selection and development. However, fully utilizing deep learning techniques for optimization across the drug development pipeline remains an ongoing challenge. Materials and Methods: A comprehensive literature review was conducted using major bibliographic databases including PubMed, Web of Science, and Scopus. Search terms included combinations of "deep learning", "drug discovery", "precision medicine", "biomedical data", and "neural networks". Over 200 papers published between 2010-2023 related to deep learning applications in pharmacology and genomics were identified and reviewed. Results: Deep learning has been widely applied at various stages of the drug discovery process including target identification/prioritization, lead generation/optimization, and prediction of molecular properties. Convolutional neural networks are commonly used for the representation and classification of biological sequence and image data for tasks such as gene expression analysis and pathogen detection from microscopy images. Graph neural networks effectively model compound structures and interactome networks to predict molecular bindings and disease associations. Multi-modal neural networks integrate diverse data types for personalized treatment response prediction and biomarker discovery. Challenges remain around data and model interpretation, generalization to new targets/diseases, and integration across domains. Discussion: While deep learning has shown promise, rigorous benchmarking and validation on real-world clinical endpoints are still needed to establish usefulness in decision-making. Data and model transparency must be improved to enable scientific insights. Privacy and security risks accompanying "real world" biomedical big data will require ethical practices. Standardization and sharing of resources/protocols could accelerate progress by enabling comparison of techniques. Combining deep learning with other AI paradigms like causal inference may further improve utility in drug discovery and precision healthcare. Conclusion: Deep neural networks demonstrate potential for optimizing drug development and precision medicine applications. Continued advancement relies on addressing challenges around data, models, validation, and ethics. Multi-disciplinary collaborations integrating machine learning, molecular biology, medicine, and other domains are needed to fully realize benefits to patients.

Industry-scale application and evaluation of deep learning for drug target prediction

Applications of Deep-Learning in Exploiting Large-Scale and Heterogeneous Compound Data in Industrial Pharmaceutical Research

The rise of deep learning in drug discovery

The Next Era: Deep Learning in Pharmaceutical Research

Implementation of Deep Learning in Drug Design

Developing Deep Learning Applications for Life Science and Pharma Industry

Deep learning in target prediction and drug repositioning: Recent advances and challenges

Exploiting machine learning for end-to-end drug discovery and development

Artificial intelligence to deep learning: machine intelligence approach for drug discovery

DeepCRE: Transforming Drug R&D via AI-Driven Cross-drug Response Evaluation

A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network

Evaluating deep neural networks in optimizing drug discovery and precision medicine: A review

A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications

Deep learning for in vitro prediction of pharmaceutical formulations

A compact review of progress and prospects of deep learning in drug discovery

deepDR: a network-based deep learning approach to in silico drug repositioning

Deep-Learning-Based Drug-Target Interaction Prediction.

A Systematic Review of Deep Learning Methodologies Used in the Drug Discovery Process with Emphasis on In Vivo Validation

Deep Learning-Based HCS Image Analysis for the Enterprise

DrugAI: a multi-view deep learning model for predicting drug-target activating/inhibiting mechanisms

DeepREAL: a deep learning powered multi-scale modeling framework for predicting out-of-distribution ligand-induced GPCR activity